Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Bosentan is known to be effective for SSc-associated pulmonary arterial hypertension (PAH), but data regarding long-term outcomes are scarce. In addition, although it has been shown to prevent the ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

You have full access to this article via your institution. Pulmonary arterial hypertension (PAH) is a chronic progressive disease characterized by endothelial cell (EC) dysfunction, substantial ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial hypertension market.

The ongoing SOTERIA study suggests that sotatercept provides a favourable long-term safety and efficacy profile for adults with pulmonary hypertension.

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...

Boosting MTMR7 production reversed signs of pulmonary arterial hypertension in a mouse model of PAH and may serve as a ...